New combo therapy aims to stall rare Cancer's return
NCT ID NCT04794127
First seen Feb 22, 2026 · Last updated May 13, 2026 · Updated 12 times
Summary
This study tested whether adding pioglitazone (a diabetes drug) to trabectedin (a chemotherapy) can better control liposarcoma, a rare soft-tissue cancer. Ten adults whose tumors had stopped growing on trabectedin alone received the combination. The goal was to see if the combo could shrink tumors or keep them stable longer, while monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIPOSARCOMA, DEDIFFERENTIATED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fondazione IRCCS Istituto Nazionale Tumori
Milan, MI, 20133, Italy
Conditions
Explore the condition pages connected to this study.